Acid sphingomyelinase deficiency in France: a retrospective survival study
Wladimir Mauhin,Nathalie Guffon,Marie T Vanier,Roseline Froissart,Aline Cano,Claire Douillard,Christian Lavigne,Bénédicte Héron,Nadia Belmatoug,Yurdagül Uzunhan,Didier Lacombe,Thierry Levade,Aymeric Duvivier,Ruth Pulikottil-Jacob,Fernando Laredo,Samia Pichard,Olivier Lidove,ASSUR Study Group,Marie-Thérèse Abi-Wardé,Marc Berger,Emilie Berthoux,Aurélie Cabannes-Hamy,Fabrice Camou,Pascal Cathebras,Vincent Grobost,Jérémy Keraen,Alice Kuster,Bertrand Lioger,Anas Mehdaoui,Claire Merlot,Martin Michaud,Martine-Louise Reynaud-Gaubert,Fréderic Schlemmer,Amélie Servettaz,Chloé Stavris,Sébastien Trouillier
DOI: https://doi.org/10.1186/s13023-024-03234-6
2024-08-05
Abstract:Background: Acid sphingomyelinase deficiency (ASMD) or Niemann-Pick disease types A, A/B, and B is a progressive, life-limiting, autosomal recessive disorder caused by sphingomyelin phosphodiesterase 1 (SMPD1) gene mutations. There is a need to increase the understanding of morbidity and mortality across children to adults diagnosed with ASMD. Methods: This observational retrospective survey analysed medical records of patients with ASMD with retrievable data from 27 hospitals in France, diagnosed/followed up between 1st January 1990 and 31st December 2020. Eligible records were abstracted to collect demographic, medical/developmental history, and mortality data. Survival outcomes were estimated from birth until death using Kaplan-Meier survival analyses; standardised mortality ratio (SMR) was also explored. Results: A total of 118 medical records of patients with ASMD (type B [n = 94], type A [n = 15], and type A/B [n = 9]) were assessed. The majority of patients were males (63.6%); the median [range] age at diagnosis was 8.0 [1.0-18.0] months (type A), 1.0 [0-3] year (type A/B), and 5.5 [0-73] years (type B). Overall, 30 patients were deceased at the study completion date; the median [range] age at death for patients with ASMD type A (n = 14) was 1 [0-3.6] year, type A/B (n = 6) was 8.5 [3.0-30.9] years, and type B (n = 10) was 57.6 [3.4-74.1] years. The median [95% confidence interval (CI)] survival age from birth in patients with ASMD type A and type A/B was 2.0 [1.8-2.7] years and 11.4 [5.5-18.5] years, respectively. Survival analysis in ASMD type B was explored using SMR [95% CI] analysis (3.5 [1.6-5.9]), which showed that age-specific deaths in the ASMD type B population were 3.5 times more frequent than those in the general French population. The causes of death were mostly severe progressive neurodegeneration (type A: 16.7%), cancer (type B: 16.7%), or unspecified (across groups: 33.3%). Conclusions: This study illustrated a substantial burden of illness with high mortality rates in patients with ASMD, including adults with ASMD type B, in France.